| Name | Title | Contact Details |
|---|
Cooley Dickinson Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cooley Dickinson Hospital is based in Northampton, MA. You can find more information on Cooley Dickinson Hospital at www.cooley-dickinson.org
ACIST Medical Systems is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baptist St. Anthony Health System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Amarillo, TX. To find more information about Baptist St. Anthony Health System, please visit www.bsahs.org
Heyday is a people-first skincare company, bringing together human touch, expertise, and data to personalize and empower people to take care of their skin. We opened our first retail location in 2015 – taking the facial and indulgence out of the spa, elevating the estheticians as the experts they are, and removing the overwhelm out of building an at-home skincare routine. Today, we have 9 locations in New York, Los Angeles, and Philadelphia. We`ve performed 225,000 facials, collected data on skincare conditions, preferences, and purchases, and become an employer of choice for a world-class team of estheticians we call Heyday Skin Therapists. Our next chapter is to take these ingredients and create unparalleled personalization and guidance across content, communities, recommendations, and services in both our physical stores and our e-commerce experience. `Heyday` means a period of your life when you`re feeling at your best. Above all, we exist to help people achieve their `heyday` – to show up in the world as their best selves, every day. We start with the skin you`re in.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.